{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:19:18Z","timestamp":1792801158625,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Natural Science Foundation for young scientists","award":["81502893"],"award-info":[{"award-number":["81502893"]}]},{"name":"Zhejiang Provincial Natural Science Foundation for the youth of China","award":["LQ15H020006"],"award-info":[{"award-number":["LQ15H020006"]}],"id":[{"id":"https:\/\/ror.org\/04aqat463","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Zhejiang Province Science and Technology Agency","award":["LY19H260004,2014C33160"],"award-info":[{"award-number":["LY19H260004,2014C33160"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Kawasaki disease (KD) is the leading cause of acquired heart disease in children, and is steadily increasing in prevalence in East Asia. KD is often complicated by coronary artery damage, including dilatation and\/or aneurysms. Aspirin is used with intravenous immunoglobulin (IVIG) to prevent coronary artery abnormalities in KD. However, the role and optimal dose of aspirin remain controversial. Identifying the dose of aspirin in the acute phase will facilitate development of a more appropriate treatment strategy in improving the outcome of KD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 2369 patients with KD were retrospectively analyzed and divided into three groups according to the aspirin dose: 510 in group 1 (20\u201329\u2009mg\/kg\/day), 1487 in group 2 (30\u201339\u2009mg\/kg\/day), and 372 in group 3 (40\u201350\u2009mg\/kg\/day). The differences in laboratory data, rate of IVIG resistance and coronary artery damage were compared among the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was no difference in the incidence of coronary artery aneurysms (CAAs) in group 1 compared with groups 2 and 3 (2\u2009weeks of illness: 2.94% vs. 1.90% vs. 3.36%; 3\u20134\u2009weeks of illness: 1.94% vs. 2.32% vs. 2.65%). The risk for developing CAA was not reduced at 2\u2009weeks of illness onset in groups 2 and 3 compared with group 1 (adjusted OR\u2009=\u20091.05, 95% confidence interval: 0.34\u20133.18; aOR\u2009=\u20091.81, 95% CI: 0.42\u20137.83). Furthermore, the risk for developing CAA was not reduced at 3\u20134\u2009weeks of illness onset in groups 2 and 3 (aOR\u2009=\u20092.63, 95% CI: 0.61\u201311.28; aOR\u2009=\u20090.52, 95% CI: 0.03\u20139.54). There was no significant difference in the rate of IVIG resistance among the groups. Platelet levels after IVIG treatment in group 1 were significantly lower than those in groups 2 and 3 (522.29\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L, 544.69\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L, and 557.77\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.013). C reactive protein of the 30-40\u2009mg\/kg*day group was slightly higher than the other two groups. (7.76, 8.00, and 7.01\u2009mg\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.028).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Aspirin at the dose of 20\u201329\u2009mg\/kg\/day dose not increase the risk of coronary artery damage and IVIG resistance compared with the dose of 30\u201350\u2009mg\/kg\/day. This low dose may have a lower risk for a potential effect on liver function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-020-00432-x","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T14:03:52Z","timestamp":1591884232000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Effect of different doses of aspirin on the prognosis of Kawasaki disease"],"prefix":"10.1186","volume":"18","author":[{"given":"Jinxin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyao","family":"Hang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoping","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixian","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"key":"432_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(04)16814-1","volume":"364","author":"JC Burns","year":"2004","unstructured":"Burns JC, Glode MP. Kawasaki syndrome. Lancet. 2004;364:533\u201344.","journal-title":"Lancet"},{"key":"432_CR2","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/INF.0000000000001474","volume":"36","author":"GB Kim","year":"2017","unstructured":"Kim GB, Park S, Eun LY, et al. Epidemiology and clinical features of Kawasaki disease in South Korea, 2012-2014. Pediatr Infect Dis J. 2017;36:482\u20135.","journal-title":"Pediatr Infect Dis J"},{"key":"432_CR3","doi-asserted-by":"publisher","first-page":"E1009","DOI":"10.1542\/peds.2013-2936","volume":"133","author":"J Saundankar","year":"2014","unstructured":"Saundankar J, Yim D, Itotoh B, et al. The epidemiology and clinical features of Kawasaki disease in Australia. Pediatrics. 2014;133:E1009\u201314.","journal-title":"Pediatrics"},{"key":"432_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/INF.0b013e3181812ca4","volume":"28","author":"A Harnden","year":"2009","unstructured":"Harnden A, Mayon-White R, Perera R, et al. Kawasaki disease in England ethnicity, deprivation, and respiratory pathogens. Pediatr Infect Dis J. 2009;28:21\u20134.","journal-title":"Pediatr Infect Dis J"},{"key":"432_CR5","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1542\/peds.111.5.1124","volume":"111","author":"RKR Chang","year":"2003","unstructured":"Chang RKR. The incidence of Kawasaki disease in the United States did not increase between 1988 and 1997. Pediatrics. 2003;111:1124\u20135.","journal-title":"Pediatrics"},{"key":"432_CR6","doi-asserted-by":"crossref","unstructured":"Makino N, Nakamura Y, Yashiro M et al. The nationwide epidemiologic survey of Kawasaki disease in Japan, 2015-2016. Pediatr Int 2019.","DOI":"10.1111\/ped.13809"},{"key":"432_CR7","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","volume":"135","author":"BW McCrindle","year":"2017","unstructured":"McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and Long-term Management of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135:e927\u201399.","journal-title":"Circulation"},{"key":"432_CR8","first-page":"2521","volume":"78","author":"Group JCSJW","year":"2014","unstructured":"Group JCSJW. Guidelines for diagnosis and management of cardiovascular sequelae in Kawasaki disease (JCS 2013). Digest version Circ J. 2014;78:2521\u201362.","journal-title":"Digest version Circ J"},{"key":"432_CR9","doi-asserted-by":"crossref","unstructured":"Dallaire F, Fortier-Morissette Z, Blais S, et al. Aspirin dose and prevention of coronary abnormalities in Kawasaki disease. Pediatrics. 2017;139.","DOI":"10.1542\/peds.2017-0098"},{"key":"432_CR10","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1097\/INF.0b013e31828e887f","volume":"32","author":"PP Fu","year":"2013","unstructured":"Fu PP, Du ZD, Pan YS. Novel predictors of intravenous immunoglobulin resistance in Chinese children with Kawasaki disease. Pediatr Infect Dis J. 2013;32:e319\u201323.","journal-title":"Pediatr Infect Dis J"},{"key":"432_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1203\/PDR.0b013e3181e67ce8","volume":"68","author":"S Fu","year":"2010","unstructured":"Fu S, Gong F, Xie C, et al. S100A12 on circulating endothelial cells surface in children with Kawasaki disease. Pediatr Res. 2010;68:165\u20138.","journal-title":"Pediatr Res"},{"key":"432_CR12","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1542\/peds.63.2.175","volume":"63","author":"H Kato","year":"1979","unstructured":"Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics. 1979;63:175\u20139.","journal-title":"Pediatrics"},{"key":"432_CR13","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1056\/NEJM199106063242305","volume":"324","author":"JW Newburger","year":"1991","unstructured":"Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633\u20139.","journal-title":"N Engl J Med"},{"key":"432_CR14","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/S0022-3476(97)70038-6","volume":"131","author":"M Terai","year":"1997","unstructured":"Terai M, Shulman ST. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. J Pediatr. 1997;131:888\u201393.","journal-title":"J Pediatr"},{"key":"432_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/ped.12317","volume":"56","author":"Research Committee of the Japanese Society of Pediatric C, Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki D","year":"2014","unstructured":"Research Committee of the Japanese Society of Pediatric C, Cardiac Surgery Committee for Development of Guidelines for Medical Treatment of Acute Kawasaki D. Guidelines for medical treatment of acute Kawasaki disease: report of the research Committee of the Japanese Society of pediatric cardiology and cardiac surgery (2012 revised version). Pediatr Int. 2014;56:135\u201358.","journal-title":"Pediatr Int"},{"key":"432_CR16","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1016\/j.ijcard.2013.06.027","volume":"168","author":"S Ogata","year":"2013","unstructured":"Ogata S, Tremoulet AH, Sato Y, et al. Coronary artery outcomes among children with Kawasaki disease in the United States and Japan. Int J Cardiol. 2013;168:3825\u20138.","journal-title":"Int J Cardiol"},{"key":"432_CR17","doi-asserted-by":"crossref","unstructured":"Kuo HC, Guo MMH, Lo MH, et al. Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial. BMC Pediatr. 2018;18.","DOI":"10.1186\/s12887-018-1180-1"},{"key":"432_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/jpc.13816","volume":"54","author":"XJ Huang","year":"2018","unstructured":"Huang XJ, Huang P, Zhang L, et al. Is aspirin necessary in the acute phase of Kawasaki disease? J Paediatr Child Health. 2018;54:661\u20134.","journal-title":"J Paediatr Child Health"},{"key":"432_CR19","doi-asserted-by":"crossref","unstructured":"Platt B, Belarski E, Manaloor J, et al. Comparison of risk of recrudescent fever in children with Kawasaki disease treated with intravenous immunoglobulin and low-dose vs high-dose aspirin. JAMA Netw Open. 2020;3.","DOI":"10.1001\/jamanetworkopen.2019.18565"},{"key":"432_CR20","doi-asserted-by":"crossref","unstructured":"Zheng XL, Yue P, Liu L, et al. Efficacy between low and high dose aspirin for the initial treatment of Kawasaki disease: current evidence based on a meta-analysis. PLoS One. 2019;14.","DOI":"10.1371\/journal.pone.0217274"},{"key":"432_CR21","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/pr.2018.44","volume":"83","author":"K Migally","year":"2018","unstructured":"Migally K, Braunlin EA, Zhang L, Binstadt BA. Duration of high-dose aspirin therapy does not affect long-term coronary artery outcomes in Kawasaki disease. Pediatr Res. 2018;83:1136\u201345.","journal-title":"Pediatr Res"},{"key":"432_CR22","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.2147\/DDDT.S163705","volume":"12","author":"L Pi","year":"2018","unstructured":"Pi L, Che D, Long HF, et al. Immature platelets and antiplatelet therapy response to aspirin in Kawasaki disease. Drug Design Development and Therapy. 2018;12:1353\u201362.","journal-title":"Drug Design Development and Therapy"},{"key":"432_CR23","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/acr.23504","volume":"70","author":"A Dhanrajani","year":"2018","unstructured":"Dhanrajani A, Chan M, Pau S, et al. Aspirin dose in Kawasaki disease: the ongoing Battle. Arthritis Care Res. 2018;70:1536\u201340.","journal-title":"Arthritis Care Res"},{"key":"432_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jpeds.2016.12.019","volume":"184","author":"GB Kim","year":"2017","unstructured":"Kim GB, Yu JJ, Yoon KL, et al. Medium- or Higher-Dose Acetylsalicylic Acid for Acute Kawasaki Disease and Patient Outcomes. J Pediatr. 2017;184:125\u2013129.e121.","journal-title":"J Pediatr"},{"key":"432_CR25","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/S0022-3476(05)82168-7","volume":"118","author":"G Koren","year":"1991","unstructured":"Koren G, Silverman E, Sundel R, et al. Decreased protein binding of salicylates in Kawasaki disease. J Pediatr. 1991;118:456\u20139.","journal-title":"J Pediatr"},{"key":"432_CR26","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/INF.0b013e31825c4d7c","volume":"31","author":"LS Callinan","year":"2012","unstructured":"Callinan LS, Tabnak F, Holman RC, et al. Kawasaki syndrome and factors associated with coronary artery abnormalities in California. Pediatr Infect Dis J. 2012;31:894\u20138.","journal-title":"Pediatr Infect Dis J"},{"key":"432_CR27","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00431-009-0925-0","volume":"168","author":"D Song","year":"2009","unstructured":"Song D, Yeo Y, Ha K, et al. Risk factors for Kawasaki disease-associated coronary abnormalities differ depending on age. Eur J Pediatr. 2009;168:1315\u201321.","journal-title":"Eur J Pediatr"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-020-00432-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-020-00432-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-020-00432-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T18:53:01Z","timestamp":1666896781000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-020-00432-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["432"],"URL":"https:\/\/doi.org\/10.1186\/s12969-020-00432-x","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]},"assertion":[{"value":"6 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local ethics committee, The Second Affiliated Hospital and Yuying Children\u2019s Hospital, China.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}